Skip to main content

BUPRENORPHINE JUNO; BUPRENORPHINE JN; BUPRESPAN; BUPRENORPHINE DB (Juno Pharmaceuticals Pty Ltd)

Product name
BUPRENORPHINE JUNO; BUPRENORPHINE JN; BUPRESPAN; BUPRENORPHINE DB
Date registered
Evaluation commenced
Decision date
Approval time
210 (255 working days)
Active ingredients
buprenorphine
Registration type
New generic medicine
Indication

BUPRENORPHINE JUNO; BUPRENORPHINE JN; BUPRESPAN; BUPRENORPHINE DB (transdermal drug delivery system) is indicated for the management of moderate to severe pain

Help us improve the Therapeutic Goods Administration site